首页 › 急性髓系白血病 › 纽约州

纽约州的急性髓系白血病临床试验

纽约州有 71 项针对急性髓系白血病的研究正在招募参与者。

纽约州的城市

官方研究文本（英文）

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

Montefiore Medical Center - Moses Campus /ID# 279399, The Bronx

招募中2/3 期

18 岁及以上 · 所有性别 · 更新于 2026年10月2日 · NCT07581002

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Roswell Park Cancer Institute, Buffalo

招募中2 期

60 岁及以上 · 所有性别 · 更新于 2026年10月2日 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Queens Hospital Center, Jamaica
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Stony Brook University Medical Center, Stony Brook

招募中观察性研究欢迎健康志愿者

40 至 75 岁 · 所有性别 · 更新于 2026年10月2日 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Memorial Sloan Kettering Commack, Commack
Memorial Sloan Kettering Westchester, Harrison
Memorial Sloan Kettering Cancer Center, New York
以及另外 1 项

招募中1 期

18 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT06484062

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Memorial Sloan Kettering Cancer Center, New York

招募中1 期

12 至 78 岁 · 所有性别 · 更新于 2026年9月29日 · NCT03802695

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Commack, Commack
Mount Sinai Hospital, New York
以及另外 5 项

招募中2 期

18 至 59 岁 · 所有性别 · 更新于 2026年9月28日 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Roswell Park Comprehensive Cancer Center, Buffalo
Memorial Sloan Kettering Cancer Center, New York
New York Presbyterian - Weill Cornell, New York
以及另外 2 项

招募中3 期

18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Commack, Commack
Northwell Health/Center for Advanced Medicine, Lake Success
以及另外 9 项

招募中2 期

18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT05564390

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Roswell Park Cancer Institute, Buffalo

招募中1 期

18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT06871410

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Memorial Sloan Kettering Cancer Center, New York

招募中1 期

21 岁及以下 · 所有性别 · 更新于 2026年9月23日 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Commack, Commack
Northwell Health/Center for Advanced Medicine, Lake Success
以及另外 5 项

招募中2 期

18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT06317649

A Study of CRD3874-SI in People With Leukemia

Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack
Memorial Sloan Kettering Westchester (All protocol activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
以及另外 1 项

招募中1 期

18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT07661095

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Commack, Commack
Memorial Sloan Kettering Westchester, Harrison
以及另外 4 项

招募中2 期

18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Commack, Commack
Memorial Sloan Kettering Westchester, Harrison
以及另外 9 项

招募中2 期

18 至 59 岁 · 所有性别 · 更新于 2026年9月22日 · NCT05554406

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Memorial Sloan Kettering Cancer Center, New York

招募中1/2 期

12 岁及以上 · 所有性别 · 更新于 2026年9月18日 · NCT06284486

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Albany Medical Center, Albany
Maimonides Medical Center, Brooklyn
Roswell Park Cancer Institute, Buffalo
以及另外 11 项

招募中3 期

6 Months – 21 Years · 所有性别 · 更新于 2026年9月17日 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Montefiore Medical Center, New York

招募中1/2 期

30 Days · 所有性别 · 更新于 2026年9月16日 · NCT04065399

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Weill Cornell, New York
Clinical Research Allicance, Westbury

招募中2 期

18 岁及以上 · 所有性别 · 更新于 2026年9月16日 · NCT06824168

A Telehealth Advance Care Planning Intervention

University of Rochester, Rochester

招募中

60 岁及以上 · 所有性别 · 更新于 2026年9月11日 · NCT05875805

Cord Blood Transplant in Adults With Blood Cancers

Memorial Sloan Kettering Cancer Center, New York

招募中2 期

21 至 65 岁 · 所有性别 · 更新于 2026年9月11日 · NCT05884333

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

Roswell Park Comprehensive Cancer Center, Buffalo

招募中1/2 期

18 岁及以上 · 所有性别 · 更新于 2026年9月11日 · NCT06969430

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

New York Medical College /ID# 275597, Valhalla

招募中1 期

6 Months – 17 Years · 所有性别 · 更新于 2026年9月9日 · NCT07306832

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Albany Medical Center, Albany
Montefiore Medical Center - Moses Campus, The Bronx

招募中3 期

1 至 25 岁 · 所有性别 · 更新于 2026年9月4日 · NCT07022678

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
Montefiore Medical Center, New York

招募中1 期

18 岁及以上 · 所有性别 · 更新于 2026年8月25日 · NCT06533761

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Albany Medical Center, Albany
Maimonides Medical Center, Brooklyn
NYU Langone Hospital - Long Island, Mineola
以及另外 7 项

招募中1/2 期

22 岁及以下 · 所有性别 · 更新于 2026年8月25日 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Columbia University Irving Medical Center, New York
Memorial Sloan Kettering Cancer Center - New York, New York
Cohen Children's Medical Center, Queens

招募中3 期

29 Days – 21 Years · 所有性别 · 更新于 2026年8月24日 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

State University of New York at Buffalo, Buffalo
Icahn School of Medicine at Mount Sinai, New York
Columbia University, New York
以及另外 1 项

招募中3 期

18 岁及以上 · 所有性别 · 更新于 2026年8月20日 · NCT07007312

Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)

Stony Brook Cancer Center, Stony Brook

招募中观察性研究

18 岁及以上 · 所有性别 · 更新于 2026年8月20日 · NCT06297551

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Roswell Park Comprehensive Cancer Center, Buffalo
Northwell Health, LLC PRIME, Lake Success
Memorial Sloan Kettering Cancer Center, New York
以及另外 3 项

招募中1 期

18 岁及以上 · 所有性别 · 更新于 2026年8月20日 · NCT06001788

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

NYU Langone Health, New York

招募中1 期

18 岁及以上 · 所有性别 · 更新于 2026年8月18日 · NCT06656494

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

New York Presbyterian Hospital-Columbia University Medical Center, New York

招募中4 期

18 岁及以上 · 所有性别 · 更新于 2026年8月11日 · NCT07486713

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Memorial Sloan- Kettering Cancer Center, New York

招募中1 期

1 至 30 岁 · 所有性别 · 更新于 2026年8月3日 · NCT06177067

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Research Site, New York

招募中1/2 期

16 岁及以上 · 所有性别 · 更新于 2026年7月20日 · NCT07155226

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

University of Rochester Medical Center (URMC), Rochester

招募中3 期

18 至 75 岁 · 所有性别 · 更新于 2026年7月17日 · NCT05429632

A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
以及另外 1 项

招募中2 期

60 岁及以上 · 所有性别 · 更新于 2026年7月17日 · NCT07392242